Skip to main content
VCbacked
Log inGet Started

Superluminal Medicines

Boston, United States

Superluminal Medicines is a generative biological and chemical company that innovates drug discovery and development processes.

$120.0M raised
Sep 2024
Series A
BiotechnologyMedicalPharmaceutical

Top Investors

Insight PartnersGaingelsNVIDIAEli LillyRA Capital Management

Founder Contacts

19,000+ verified contacts
Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Superluminal Medicines

How much funding has Superluminal Medicines raised?
Superluminal Medicines has raised $120.0M in total funding. The most recent round was Series A. The last funding was announced in September 2024.
Who are Superluminal Medicines's investors?
Superluminal Medicines's investors include Insight Partners, Gaingels, NVIDIA, Eli Lilly, RA Capital Management.
Where is Superluminal Medicines headquartered?
Superluminal Medicines is headquartered in Boston, United States.
What does Superluminal Medicines do?
Superluminal Medicines is a generative biological and chemical company that innovates drug discovery and development processes.
What stage is Superluminal Medicines at?
Superluminal Medicines is at the Series A stage.
Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .

MLA
"Superluminal Medicines — Funding & Investors." VCBacked, September 9, 2024, https://www.vcbacked.co/company/superluminal-medicines. Accessed June 3, 2026.
APA
VCBacked. (2024). Superluminal Medicines — Funding & Investors. Retrieved June 3, 2026, from https://www.vcbacked.co/company/superluminal-medicines
Wikipedia (cite web)
{{cite web |title=Superluminal Medicines — Funding & Investors |url=https://www.vcbacked.co/company/superluminal-medicines |website=VCBacked |access-date=June 3, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated .

Similar Companies in Biotechnology

View all
Virtuoso Surgical
Nashville
Pharvaris
Zug
Odyssey Therapeutics
Boston$213.0M
Tempus
Chicago
Anagram Therapeutics
Boston
Prenetics
Hong Kong